Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 14,113 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 2 Interventional

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

NCT02282215
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Infection
Interventions
CLT-008, G-CSF
Biological
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 30, 2026, 11:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

NCT01060878
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris

NCT02932306
View directory record Official record
Conditions
Acne
Interventions
IDP-121 Lotion, IDP-121 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
39
States / cities
Guntersville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance

NCT05316233
View directory record Official record
Conditions
Neck Lines
Interventions
VOLITE XC
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Newport Beach, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

NCT02597933
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752
View directory record Official record
Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
CBP-201, placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

SB-480848 In Subjects With Coronary Heart Disease

NCT00269048
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-480848, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 11:17 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

NCT07869043
View directory record Official record
Conditions
Asthma
Interventions
tilrekimig, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Austin, Texas • Tomball, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL, placebo-metreleptin 1 mL, Pramlintide acetate 180 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 30, 2026, 11:17 AM EDT
Not listed Not applicable Interventional

Breast Mesh Used in Two-staged Breast Reconstruction

NCT04967976
View directory record Official record
Conditions
Breast Cancer, Radiation, Breast Reconstruction, Synthetic Mesh
Interventions
TiLoop Bra mesh in expander-implant breast reconstrution, sub-pectoral expander-implant breast reconstruction
Procedure
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults

NCT00945893
View directory record Official record
Conditions
Healthy
Interventions
MEDI3414 [Influenza A/H1N1 live attenuated, intranasal], Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Miami, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines

NCT00690716
View directory record Official record
Conditions
Migraine
Interventions
Nasal CO2, Inactive Placebo
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Stanford, California • East Hartford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

NCT03964493
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections
Interventions
TNP-2092, Vancomycin
Drug
Lead sponsor
TenNor Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232
View directory record Official record
Conditions
Central Neuropathic Pain, Multiple Sclerosis
Interventions
AVP-923-45, AVP-923-30, AVP-923-20, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

NCT01374438
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MSDC-0160, Placebo
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

NCT02338648
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Multisite Controlled Trial of Cocaine Vaccine

NCT00969878
View directory record Official record
Conditions
Cocaine Dependence
Interventions
TA-CD Vaccination, Placebo Injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 30, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

NCT05843578
View directory record Official record
Conditions
Fibrostenotic Crohn's Disease
Interventions
AGMB-129, Placebo
Drug
Lead sponsor
Agomab Spain S.L.U.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 11:17 AM EDT